Argos Therapeutics, Inc.
ARGS
ARGS was delisted on the 24th of April, 2018.
29 hedge funds and large institutions have $2.89M invested in Argos Therapeutics, Inc. in 2017 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 11 closing their positions.
2,556% more call options, than puts
Call options by funds: $956K | Put options by funds: $36K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
15% less funds holding
Funds holding: 34 → 29 (-5)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
45% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 11
48% less capital invested
Capital invested by funds: $5.57M → $2.89M (-$2.67M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$160K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$36K |
| 3 |
KeyBank National Association
Cleveland,
Ohio
|
+$28.7K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$21.5K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$17.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$40K |
| 2 |
ECM
Element Capital Management
New York
|
-$30K |
| 3 |
Morgan Stanley
New York
|
-$19K |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$17K |
| 5 |
LP
LMR Partners
London,
United Kingdom
|
-$16K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ECM
26
Element Capital Management
New York
| – | -$30K | -4,140 | Closed |
|
|
27
Morgan Stanley
New York
| – | -$19K | -2,660 | Closed |
|
|
PP
28
Paloma Partners
Greenwich,
Connecticut
| – | -$17K | -2,305 | Closed |
|
|
LP
29
LMR Partners
London,
United Kingdom
| – | -$16K | -2,251 | Closed |
|
30
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$11K | -1,564 | Closed |
|
31
Citadel Advisors
Miami,
Florida
| – | -$7K | -899 | Closed |
|
|
CG
32
Cutler Group
San Francisco,
California
| – | -$3.55K | -740 | -89% |
|
33
Squarepoint
New York
| – | -$5K | -715 | Closed |
|
34
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$2.3K | -480 | -85% |
|
35
Group One Trading
Chicago,
Illinois
| – | -$2.18K | -454 | -84% |
|
36
Barclays
London,
United Kingdom
| – | -$1.57K | -328 | -98% |
|
37
Creative Planning
Overland Park,
Kansas
| – | -$2K | -300 | Closed |
|
38
Bank of America
Charlotte,
North Carolina
| – | -$1.33K | -277 | -88% |
|
|
TRCT
39
Tower Research Capital (TRC)
New York
| – | -$2K | -246 | Closed |
|
40
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$168 | -35 | -95% |
|
ARGS Hedge Fund Activity: Q3 2017 in Review
29 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Argos Therapeutics, Inc. (ARGS) for Q3 2017, worth a combined $2.89M — down 48% from $5.57M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of ARGS and 6 opened new positions — a net loss of 5 holders — while 8 trimmed existing stakes and 6 added.
The largest buyer was Wasatch Advisors, opening a new position worth an estimated $160K. The largest seller was Goldman Sachs, exiting entirely with an estimated $40K sold.
- 29 institutional investors held Argos Therapeutics, Inc. (ARGS) as of Q3 2017, down from 34 in Q2 2017.
- Funds reported $2.89M of Argos Therapeutics, Inc. stock for Q3 2017, down 48% quarter-over-quarter.
- 6 funds opened new Argos Therapeutics, Inc. positions in Q3 2017 and 11 closed out, a net change of -5 holders.
- The largest Argos Therapeutics, Inc. buyer in Q3 2017 was Wasatch Advisors, an estimated $160K added.
- The largest Argos Therapeutics, Inc. seller in Q3 2017 was Goldman Sachs, an estimated $40K sold.
Based on aggregated 13F filings for Q3 2017.